​

DiaMedica Therapeutics (DMAC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

DMAC Stock Forecast

DiaMedica Therapeutics (DMAC) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $8.33, with a high of $10.00 and a low of $7.00. This represents a 21.08% increase from the last price of $6.88.

$2 $3 $4 $5 $6 $7 $8 $9 $10 High: $10 Avg: $8.33 Low: $7 Last Closed Price: $6.88

DMAC Stock Rating

DiaMedica Therapeutics stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 0 6 Strong Sell Sell Hold Buy Strong Buy

DMAC Price Target Upside V Benchmarks

TypeNameUpside
StockDiaMedica Therapeutics21.08%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$6.88$6.88$6.88
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2512---3
Sep, 2512---3
Aug, 2512---3
Jul, 2512---3
Jun, 2512---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 07, 2024Bill ChappellTruist Financial$10.00$4.42126.24%45.35%
Oct 07, 2024Matthew CaufieldH.C. Wainwright$7.00$4.3660.55%1.74%
Mar 21, 2024Alex NowakCraig-Hallum$8.00$2.69197.40%16.28%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 07, 2024H.C. WainwrightBuyinitialise
Jun 22, 2023OppenheimerOutperformupgrade
Jun 22, 2023OppenheimerHoldupgrade
Jul 07, 2022Lake StreetBuyBuyhold
Jul 07, 2022Craig-HallumBuyBuyhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.60$-0.60----
Avg Forecast$-0.60$-0.59$-0.79$-0.85$-0.92$-0.54
High Forecast$-0.60$-0.58$-0.72$-0.76$-0.92$-0.54
Low Forecast$-0.60$-0.60$-0.85$-0.93$-0.92$-0.54
Surprise %-1.69%----

Revenue Forecast

$10M $19M $28M $37M $46M $55M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$54.00M$11.15M$40.47M
High Forecast---$54.00M$11.15M$40.47M
Low Forecast---$54.00M$11.14M$40.47M
Surprise %------

Net Income Forecast

$-35M $-31M $-27M $-23M $-19M $-15M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-19.38M$-24.44M----
Avg Forecast$-19.65M$-19.30M$-25.57M$-27.52M$-29.96M$-17.59M
High Forecast$-19.65M$-18.97M$-23.48M$-24.75M$-29.96M$-17.59M
Low Forecast$-19.65M$-19.62M$-27.66M$-30.29M$-29.96M$-17.59M
Surprise %-1.36%26.68%----

DMAC Forecast FAQ

Is DiaMedica Therapeutics stock a buy?

DiaMedica Therapeutics stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that DiaMedica Therapeutics is a favorable investment for most analysts.

What is DiaMedica Therapeutics's price target?

DiaMedica Therapeutics's price target, set by 6 Wall Street analysts, averages $8.33 over the next 12 months. The price target range spans from $7 at the low end to $10 at the high end, suggesting a potential 21.08% change from the previous closing price of $6.88.

How does DiaMedica Therapeutics stock forecast compare to its benchmarks?

DiaMedica Therapeutics's stock forecast shows a 21.08% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for DiaMedica Therapeutics over the past three months?

  • October 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is DiaMedica Therapeutics’s EPS forecast?

DiaMedica Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.79, marking a 31.67% increase from the reported $-0.6 in 2024. Estimates for the following years are $-0.85 in 2026, $-0.92 in 2027, and $-0.54 in 2028.

What is DiaMedica Therapeutics’s revenue forecast?

DiaMedica Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $54M, followed by $11.15M for 2027, and $40.47M for 2028.

What is DiaMedica Therapeutics’s net income forecast?

DiaMedica Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-25.567M, representing an 4.59% increase from the reported $-24.444M in 2024. Projections indicate $-27.519M in 2026, $-29.961M in 2027, and $-17.586M in 2028.